PRESENT-HF: Pulmonary REsistance Modification Under Treatment With Sacubitril/valsartaN in paTients With Heart Failure With Reduced Ejection Fraction
Study Details
Study Description
Brief Summary
MAIN OBJECTIVE. Demonstration that use of sacubitril/valsartan influences parameters of right heart catheterization, including pulmonary artery pressure, and provokes changes in pulmonary circulation resistance in patients with heart failure with reduced left ventricular ejection fraction (HFrEF) and post-capillary pulmonary hypertension (PH): both isolated post-capillary (Ipc-PH) and combined post- and pre-capillary (Cpc-PH), which we predict could improve prognosis in this group of patients.
RESEARCH HYPOTHESIS. Sacubitril/valsartan used in patients with HFrEF accompanied by pulmonary hypertension due to HFrEF will reduce pulmonary artery pressure, pulmonary vascular resistance, and the incidence of secondary end-points as listed in the protocol.
STUDY OUTLINE. PRESENT-HF will show the effects of sacubitril/valsartan on pulmonary circulation pressure in patients with HFrEF and post-capillary pulmonary hypertension (PH): both isolated post-capillary (Ipc-PH) and combined post- and pre-capillary (Cpc-PH), which is expected to improve prognosis.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Detailed Description
Non commercial, multicentre, randomised, double-blind, comparator-controlled clinical trial. Eligible patients were randomly assigned (1:1) using a secure, central, interactive, web-based response system, to intervention or comparator arm. Time of observation 13 months [1months active up titration phase + 12 months follow up].
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Sacubitril and valsartan combination Patient receive: 1 bottle with Sacubitril/Valsartan tablets and 2nd bottle with placebo to enalapril. |
Drug: Sacubitril-valsartan
level 1-24 / 26mg 2 times a day, level 2-49 / 51mg 2 times a day, level 3-97 / 103mg 2 times aday
Drug: Placebo
placebo matching for 2.5 mg, 5 mg, 10 mg of enalapril
|
| Active Comparator: Enalapril Patient receive: 1 bottle with placebo to Sacubitril/Valsartan and 2nd bottle with enalapril. |
Drug: Enalapril
level 1-2.5 mg twice a day, level 2-5 mg twice a day, level 3-10 mg twice a day
Drug: placebo
placebo matching for 24 / 26mg, 49 / 51mg, 97 / 103mg 2 of sacubitril/valsartan
|
Outcome Measures
Primary Outcome Measures
- mean pulmonary artery pressure [0-13 month]
change from baseline in mean pulmonary artery pressure (mPAP), measured invasively in Right Heart Catheterization (RHC)
- pulmonary vascular resistance [0-13 month]
change from baseline in pulmonary vascular resistance (PVR), calculated from data measured invasively in Right Heart Catheterization (RHC)
Secondary Outcome Measures
- pulmonary wedge pressure [0 -13 month]
change from baseline in pulmonary wedge pressure (PWP), measured invasively in Right Heart Catheterization (RHC)
- diastolic pressure gradient [0-13 month]
change from baseline in the diastolic pressure gradient (DPG; where DPG = diastolic mPAP -mean PWP)
- 6-minute walk test [0-13 month]
change in the 6-minute walk test (6MWT) - analysis of changes from the baseline
- spiroergometric test (CPET, Cardio-Pulmonary Exercise Test) [0-13 month]
evaluation of the parameters of the spiroergometric test - analysis of changes in relation to the baseline
- echocardiographic parameters [0-13 month]
assessment of echocardiographic parameters - analysis of changes in echocardiographic parameters assessed in transthoracic echocardiographic examination (TTE)
- composite endpoint of MACCEs (major adverse cardiac and cerebrovascular events) [0-13 month]
The incidence of the composite endpoint of MACCEs such as death from all causes, cardiac death, hospitalization due to worsening/ decompensation of heart failure (HF), stroke/ transient ischemic attack (TIA), acute coronary syndrome (ACS), the need for a heart transplant (HT), the need for a left ventricular assist device (LVAD) or biventricular(BVAD)
- hospitalization or an unplanned visit to the Emergency Department [0-13 month]
hospitalization or an unplanned visit to the Emergency Department or an unplanned outpatient visit related to HF
- unplanned intravenous administration of diuretics and/or an unplanned hospitalization [0-13 month]
the need for unplanned intravenous administration of diuretics and/or an unplanned hospitalization, outpatient visit due to the need to administer intravenous diuretics or requiring an increase in the dose of diuretics >50% from baseline
- quality of life measurements - Short Form 36 Health Survey (SF-36 questionnaire) [0-13 month]
assessment of quality of life - SF-36 questionnaire - change from the baseline, the minimum and maximum values: 0-100, higher scores mean a less disability.
- quality of life measurements - Kansas City Cardiomyopathy Questionnaire (KCCQ) [0-13 month]
assessment of quality of life - KCCQ, the minimum and maximum values: 0-100, higher scores mean higher quality of life.
- quality of life measurements - EuroQol-5 Dimensions-3 Level (EQ-5D-3L) questionnaire [0-13 month]
assessment of quality of life - EQ-5D-3L questionnaire - change from the baseline, the minimum and maximum values: 0-100, higher scores mean higher quality of life.
- quality of life measurements - The World Health Organization Quality of Life (WHOQOL) [0-13 month]
assessment of quality of life - WHOQOL - change from the baseline, the minimum and maximum values: 0-100, higher scores mean higher quality of life.
- the New York Heart Association functional classes [0-13 month]
assessment of the New York Heart Association (NYHA) functional classes - change from the baseline, the minimum and maximum values: 1-4, higher scores mean a worse outcome.
- the World Health Organization functional classes [0-13 month]
assessment of the World Health Organization (WHO) functional classes - change from the baseline, the minimum and maximum values: 1-4, higher scores mean a worse outcome.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age ≥18 years of age who are able to complete and sign the informed consent form.
-
HF patients in NYHA functional class II-IV with a reduced left ventricular ejection fraction (LVEF) ≤40% -(HFrEF) (confirmed by an examination such as echocardiography or cardiac magnetic resonance within the last 6 months) in whom right heart catheterization (RHC) reveals post-capillary or mixed pulmonary hypertension (defined on the basis of the 2015 ESC (European Society of Cardiology) guidelines: mean pulmonary artery pressure (PAPm) ≥25 mmHg and pulmonary capillary wedge pressure (PCWP)>15mmHg) were found, both of the isolated extracapillary PH (Ipc-PH) (defined on the basis of the 2015 ESC guidelines: DPG < 7 mm Hg and / or PVR ≤ 3 WU) as well as complex extra-and pre-capillary PH (Cpc-PH) (defined on the basis of the 2015 ESC guidelines: DPG ≥ 7 mm Hg and / or PVR> 3 WU).
-
Stable patients haemodynamics, which is defined as no change in diuretic use for at least 4 weeks prior to study entry.
-
HF during optimal treatment with ACE-I (angiotensin converting enzyme) /ARB (angiotensin receptor blocker), beta blocker, MRA (Mineralocorticoid Receptor Antagonists), SGLT2-I except in cases where the above-mentioned treatment was contraindicated or not tolerated.
-
Understanding and acceptance of the research assumptions and methods and signing the informed consent by the patient.
Exclusion Criteria:
-
Current treatment with S/V.
-
Cardiogenic shock.
-
Current treatment with sildenafil.
-
Patients ineligible or contraindicated for treatment with sacubitril-valsartan.
-
Patients with a history of angioedema.
-
Patients who have had a heart transplant or have had a circulatory support device.
-
Patient on the urgent list for heart transplant.
-
Isolated right HF secondary to lung disease.
-
Documented untreated significant ventricular arrhythmia with syncope within the previous 3 months.
-
Symptomatic bradycardia or second or third degree atrioventricular block not protected by a pacemaker.
-
Factors that prevent RHC testing (e.g. very serious condition of the patient that makes it impossible to lie down, cardiogenic shock, allergy to contrast agents, etc.).
-
Pregnant or lactating women.
-
Women of childbearing age, defined as the physiological possibility of becoming pregnant, unless using two methods of contraception.
-
Acute coronary syndrome, including myocardial infarction (STEMI, NSTEMI), a condition with carotid revascularization or major cardiovascular surgery in the last 30 days.
-
Stroke or transient cerebral ischemia (TIA) within the last 3 months.
-
Previous CRT (Cardiac Resynchronization Therapy) implantation in the last 3 months or planning for CRT implantation.
-
Life expectancy <6 months.
-
Severe renal failure, eGFR (epidermal growth factor receptor) <30 ml / min / 1.73 m2(calculated according to the MDRD formula).
-
Serum potassium> 5.2 mEq/L.
-
Liver failure or elevated liver transaminases (total bilirubin> 3 mg / dL and/or ALT (Aspartate transaminase) and/or AST (Aspartate Aminotransferase) ≥3x ULN).
-
A major surgery planned within 6 months of randomization.
-
Planned coronary angioplasty or pacemaker / ICD (implantable cardioverter defibrillator) / CRT implantation within the next 6 months.
-
Severe primary valve disease (NOT secondary mitral regurgitation) or obstructive hypertrophic cardiomyopathy.
-
The presence of a malignant neoplasm of any organ system, ie clinical signs or no stable remission for at least 3 years after the end of the last treatment, with the exception of non-invasive basal cell carcinoma, squamous cell carcinoma of the skin or cervical epithelial dysplasia.
-
Diseases that significantly reduce physical performance:
-
severe COPD (chronic obstructive pulmonary disease) putting off oxygen therapy,
-
severe asthma,
-
morbid obesity (BMI> 40 kg / m2),
-
significant lower limb atherosclerosis with intense intermittent claudication.
-
Uncontrolled hypertension (SBP> 170 mmHg and / or DBP> 100 mmHg).
-
Symptomatic hypotension (SPB <90 mmHg)
-
Any situation that may make it impossible to perform the research in accordance with the protocol or express written consent in the opinion of the researcher, including abuse of alcohol, drugs or other psychoactive substances.
-
Participation in a study with a device or medicinal product within 3 months prior to randomization or 5 half-lives, whichever is longer, prior to the screening visit.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Medical University of Bialystok Clinical Hospital | Białystok | Poland | 15-276 | |
| 2 | University Clinical Centre in Gdańsk | Gdańsk | Poland | 80-952 | |
| 3 | University Clinical Hospital in Opole | Opole | Poland | 45-401 | |
| 4 | Heliodor Święcicki Clinical Hospital of the Poznań University of Medical Sciences | Poznań | Poland | 61-848 | |
| 5 | Specialist Hospital in Zabrze | Zabrze | Poland | 41-800 |
Sponsors and Collaborators
- Clinical Hospital Heliodor Swiecicki of the Medical University of Karol Marcinkowski in Poznań
- Medical Research Agency, Poland
- Medical University of Bialystok
- University of Opole
- Medical University of Gdańsk
- Medical University of Silesia
Investigators
- Principal Investigator: Ewa Straburzyńska-Migaj, Prof. MD, Heliodor Święcicki Clinical Hospital of the Poznań University of Medical Sciences
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2019/ABM/01/00078